Stocktoria
Alkermes plc. ALKS
Alkermes plc. (ALKS) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $1.5B at a 16.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.29 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-29 | JP Morgan | Neutral (main) |
| 2026-07-29 | Baird | Outperform (main) |
| 2026-07-28 | Piper Sandler | Overweight (reit) |
| 2026-07-20 | Stifel | Buy (reit) |
| 2026-07-13 | Needham | Buy (main) |
| 2026-07-02 | Mizuho | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.557 |
| Retained earnings / assets | -0.295 |
| EBIT / assets | 0.102 |
| Equity / liabilities | 2.725 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ALKS | Alkermes plc. | 5/9 | 6.24 | 38 | -5.2% |
| PAHC | PHIBRO ANIMAL HEALTH CORP | 5/9 | 3.97 | 26.6 | +27.4% |
| INDV | Indivior Pharmaceuticals, Inc. | 4/9 | -0.7 | 24.3 | +4.3% |
| NSRX | Nasus Pharma Ltd | 3/9 | -13.82 | — | — |
| PTCT | PTC THERAPEUTICS, INC. | 5/9 | 1.56 | 10.3 | +114.5% |
| PBH | Prestige Consumer Healthcare Inc. | 5/9 | 4.04 | 12.3 | -4.3% |
| ACAD | ACADIA PHARMACEUTICALS INC | 4/9 | 3.79 | 11.1 | +11.9% |
About Alkermes plc.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
FAQ
Is ALKS financially healthy?
Alkermes plc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ALKS pay a dividend?
No, Alkermes plc. does not currently pay a dividend.
How profitable is ALKS?
In FY2025, Alkermes plc. had a net margin of 16.4% and a return on equity of 13.3%.
Is ALKS overvalued or undervalued?
Alkermes plc. trades at about 35.2× trailing earnings — above its 10-year norm (10-year range 12.9×–347.7×, median 23.7×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ALKS?
The average Wall-Street price target for Alkermes plc. is $56.00, about 11.4% above the recent price, from 17 analysts (consensus: buy).
Is ALKS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Alkermes plc.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 38.0×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.